SpringWorks Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on Nasdaq (United States) and focused on precision medicine for severe rare diseases and genetically defined cancers. The company was originally formed in Delaware in August 2017 and is headquartered in Stamford, Connecticut. From the outset, SpringWorks has pursued a targeted strategy centered on small-molecule therapeutics, aiming to address patient populations with high unmet medical need and limited treatment options. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1773427/000177342722000011/swtx-20211231.htm?utm_source=openai)) SpringWorks has evolved from a clinical-stage biotech into a commercial-stage company. Its first commercial product, OGSIVEO (nirogacestat), was approved by the FDA on November 27, 2023 for adults with progressing desmoid tumors requiring systemic treatment. In 2025, the company reached another major milestone when the FDA approved GOMEKLI (mirdametinib) for adults and pediatric patients aged 2 years and older with symptomatic plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN) that are not amenable to complete resection. These approvals materially strengthen the company’s commercial profile and validate its development capabilities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm?utm_source=openai)) In competitive terms, SpringWorks is positioned as a specialty oncology and rare-disease player rather than a broad diversified pharma company. Its differentiation comes from a precision-medicine approach, deep focus on rare tumor biology, and a portfolio built around highly selected indications where clinical development can be more efficient and where meaningful treatment advances can command strong physician and patient interest. The company’s pipeline also includes efforts to expand mirdametinib beyond the U.S., including a positive CHMP opinion in Europe in 2025, which supports the possibility of future ex-U.S. commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm?utm_source=openai)) SpringWorks’ corporate history also matters for investors. The company went public in 2019, establishing itself on Nasdaq as an emerging biotech with a long development runway. More recently, in April 2025, Merck KGaA, Darmstadt, Germany announced an agreement to acquire SpringWorks, a transaction that highlights the strategic value of its rare-disease and oncology assets. For equity investors, the name sits at the intersection of commercial launch execution, regulatory expansion, and M&A optionality. That combination makes SpringWorks a notable U.S. biopharma story for investors tracking SEC Form 4 insider activity and special situations in the healthcare sector. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1773427/000155837021001708/swtx-20201231x10k.htm?utm_source=openai))